Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: Approaches are disclosed for switching transport protocol connection keys. A method of automatically changing a message authentication key at each of two endpoints of a connection in a telecommunications network comprises testing a sequence value received in each of a plurality of data segments on the connection; and selecting a next message authentication key, from among a plurality of stored message authentication keys, for use in authenticating subsequently received data segments, when the sequence value matches a specified characteristic.